1. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):S713–23.
2. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;2018(6):1–276.
3. Businesswire. FDA approves Aurinia Pharmaceuticals’ Lupkynis™ (voclosporin) for adult patients with active lupus nephritis [media release]. 25 Jan 2021. www.businesswire.com.
4. Aurinia Pharmaceuticals Inc. LupkynisTM (voclosporin) capsules, for oral use. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf. Accessed 23 Feb 2021.
5. Isotechnika Pharma Inc., Aurinia Pharmaceuticals Inc. Isotechnika merger with Aurinia to create leading nephrology company [media release]. 5 Feb 2013. http://www.auriniapharma.com.